Dr Reddy’s Q3 results: Net profit grows 2% to ₹1,403.8 crore, revenue surges 16%

Dr. Reddy’s Laboratories on Thursday, January 23 reported a 1.8% year-on-year rise in net profit to ₹1,403.8 crore in the third quarter of the 2024-25 fiscal as against ₹1,378.9 crore in the corresponding period last year.

The pharmaceutical company’s operational revenue stood at ₹8,358.6 crore in the three months ending December 31, 2024, up 15.8% from ₹7,214.8 crore during the same period last year.

Its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased by 8.9% to ₹2,298.2 crore from ₹2,110.7 in Q3 of the 2023-24 fiscal year.

"We delivered double-digit growth (revenue) aided by our newly acquired NRT(Nicotine Replacement Therapy) business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation," Dr. Reddy's Laborites' Co-Chairman & MD, G V Prasad said.

Region-wise revenue

Dr. Reddy's operational revenue from the North American market fell 9% sequentially (quarter on quarter) to ₹3,349.2 crore in Q3 FY25. It had a subdued year-on-year growth of 1%. In the corresponding period last year, its revenue from North America stood at ₹3,349.2 crore.

The company registered an astounding 143% YoY revenue growth in the European market. In Q3 FY35, it stood at ₹1,209.6 crore, compared to ₹497 crore a year ago. It grew 110%.QoQ.

Its revenue from India surged 14% year-on-year to ₹1346.4 crore in Q3 FY25. However, on a quarter-on-quarter basis, it slipped 4%. In the corresponding period last year, its revenue from the Indian market stood at ₹1,180 crore.

Dr Reddy’s closed at ₹1,290, down 0.48% on the NSE on Thursday. However, it announced its Q3 results after the market hours.